MedWatch

Ambassador views Teva CEO as important player in potential vaccine alliance

Denmark, Austria and Israel have contacted several companies in connection with a potential collaboration on vaccine production, states Israeli Ambassador to Denmark Benny Dagan, according to Børsen.

Teva CEO Kåre Schultz | Photo: Lars Krabbe/ERH

Even though Denmark's, Austria's and Israel's vaccine production collaboration is still just an idea on the drawing board, the countries have already been in contact with multiple companies, according to Danish newspaper Børsen on the basis of an interview with Israeli Ambassador to Denmark Benny Dagan.

If these countries enter into a collaboration on future vaccine production, manufacturers like Teva, led by Danish national Kåre Schultz, will play a crucial role, says Dagan, according to Børsen:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs